富祥药业(300497) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥430,793,596.45, representing a year-on-year increase of 7.41%[5] - The net profit attributable to shareholders was -¥21,962,365.13, a decrease of 3,836.04% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥22,400,820.84, a decline of 761.49% year-on-year[5] - The total comprehensive income for Q3 2023 was -¥92,909,101.51, a decline of 436.73% compared to the same period last year[10] - The company's basic earnings per share for Q3 2023 was -¥0.04, a decrease of 4,100.00% year-on-year[5] - The company's basic and diluted earnings per share were both -¥0.15, compared to ¥0.08 in the same quarter last year[25] - The company reported a net loss of -¥86,725,234.93 for the period, compared to a profit of ¥43,823,031.50 in the previous period[23] Cash Flow and Liquidity - The operating cash flow for the year-to-date was -¥16,570,141.01, a decrease of 524.67% compared to the previous year[10] - The net cash flow from financing activities decreased by 50.39% to ¥155,395,309.53 due to reduced borrowings during the reporting period[12] - The net increase in cash and cash equivalents was a decrease of 79.74%, totaling -¥205,856,935.09, influenced by operating, investing, and financing activities as well as exchange rate changes[12] - Total cash inflow from operating activities was ¥876,012,808.90, while cash outflow was ¥892,582,949.91, resulting in a net cash flow from operating activities of -¥16,570,141.01[27] - Cash and cash equivalents at the end of the period stood at ¥641,395,653.15, down from ¥1,069,410,810.42 at the end of the previous year[28] - The cash and cash equivalents decreased to ¥2,300,000.00 from ¥49,741,736.89, indicating a significant drop of approximately 95.4%[21] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥4,925,521,892.45, down 2.65% from the end of the previous year[5] - The total assets decreased to ¥4,925,521,892.45 from ¥5,059,834,182.46, a decline of about 2.6%[22] - Current liabilities totaled ¥1,263,511,708.84, slightly up from ¥1,258,857,086.95, showing a marginal increase of 0.2%[22] - The company's total liabilities decreased to ¥2,335,934,483.29 from ¥2,370,197,741.24, a reduction of approximately 1.5%[22] - The equity attributable to shareholders decreased to ¥2,592,462,374.01 from ¥2,681,239,180.97, a decline of about 3.3%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,811[14] - The largest shareholder, Bao Jianhua, holds 19.28% of shares, totaling 106,049,808 shares, with 40,990,000 shares pledged[14] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder having a substantial stake[14] - The company has a repurchase account holding 11,355,900 shares, representing 2.06% of the total share capital[15] Operational Performance - Total operating revenue for the period reached ¥1,286,439,179.08, an increase from ¥1,232,211,008.36 in the previous period, representing a growth of approximately 4.4%[23] - Total operating costs increased to ¥1,364,463,759.45 from ¥1,193,962,962.75, reflecting a rise of about 14.3%[23] - The company's operating profit turned negative at -¥86,067,400.42, compared to a profit of ¥44,797,754.09 in the previous period[23] - Research and development expenses rose to ¥63,502,264.13, up from ¥55,798,555.09, indicating an increase of approximately 13.1%[23] Other Financial Metrics - The company experienced a 65.87% decrease in government subsidies received, totaling ¥4,467,908.74 for the year-to-date[10] - The impact of exchange rate fluctuations on cash was a decrease of 72.59%, amounting to ¥2,455,896.51, primarily due to the volatility of the US dollar exchange rate[12] - The company received tax refunds amounting to ¥43,240,624.56 during the quarter, down from ¥82,106,453.68 in the previous year[27] - The company has not undergone an audit for the third quarter report[29] Strategic Outlook - The company plans to continue monitoring market conditions and adjust strategies accordingly to enhance shareholder value[15]